Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Markets
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Fed-and-SEC desk, TradeNews USA (2026-10-02): Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes. Primary source: original at CNBC Top News (cnbc.com).